In patients with sickle cell anemia, the sickling of red blood cells is known to cause end-organ damage by infarction. In some men who are affected by sickle cell anemia, the obstruction of venous outflow of the penis causes priapism, which could lead to erectile dysfunction. There is also evidence that the disease is linked to other reproductive issues in men-specifically delayed puberty, low testosterone, and sperm abnormalities-although the causes of these problems are less clear. Treatment of sickle cell anemia can have effects on the reproductive system as well. This review summarizes the findings from various publications pertaining to reproductive endocrinology, along with their conclusions and discrepancies.
INTRODUCTION
Sickle cell anemia (SCA) is a hemoglobinopathy caused by a valine to glutamate mutation on the sixth amino acid of the bglobin chain in adult hemoglobin, resulting in red blood cells having a sickle shape instead of the normal biconcave disk shape. The resulting hemoglobin is called hemoglobin S. It is the most common hemoglobinopathy and is found mostly in people of African descent and in parts of the Middle East, India, and Mediterranean countries. Around one in 12 African Americans have sickle cell trait, and one in 500 African American live births result in sickle cell disease.
Sickling of red blood cells in sickle cell anemia can cause-in addition to severe pain-ischemia and infarction of various organs, such as the spleen, liver, kidney, lungs, bone, and brain. In men with SCA, infarction of the venous outflow of the penis can also lead priapism and result in permanent impotence. Some researchers have also hypothesized that sickling could cause testicular or pituitary infarcts, which may affect puberty and fertility in male patients (Dada & Nduka, 1976; Li et al., 2003) . There have been a number of studies on the effect of SCA on the male reproductive system, and the existing research will be explored in this paper.
Of note, SCA refers specifically to the homozygous variant of the hemoglobin S mutation as mentioned above. Sickle cell disease (SCD) is an encompassing term for all variants of hemoglobinopathy which include at least one copy of hemoglobin S with another abnormal hemoglobin. When searching for articles to include in this review, only studies where the majority of subjects have SCA were included, although many of these studies also included a subset of patients with other variants of SCD in their analysis. The term SCD is used when these studies are described in the paper. However, results should not be used to generalize to all patients with SCD because of the limited number of subjects and the large number of variations that exist, which may not be well-represented in each study.
It is also important to note that many of the earlier publications included in this review were from the 1970s and 1980s, when researchers made rapid advancements in the diagnosis and treatment of sickle cell anemia. Before these advancements, patients with sickle cell anemia rarely survived past childhood. With the introduction of the pneumococcal vaccine, universal screening of newborns, and early penicillin prophylaxis, these patients are living long enough to have children and grandchildren (Frenette & Atweh, 2007) .
In addition to life-prolonging measures, advancements in treatment have allowed patients with SCA to have a better quality of life. While opioids are the mainstay of treating pain caused by the disease, blood transfusions have also been used for decades to prevent and treat sickle cell crises. Hydroxyurea is an anti-neoplastic drug that was approved for the treatment of severe SCA in 1998. It has been shown to decrease the number of painful episodes and acute chest syndrome, and increase the amount of circulating fetal hemoglobin (Benz, 2012) . And recently, hematopoietic stem cell transplant has been shown to be the only cure for SCD (Hsieh et al., 2014) .
It is therefore important to now re-explore the reproductive and endocrinological issues that these patients might have, taking into account the effect that treatment might have on the reproductive system.
GROWTH DURING CHILDHOOD AND PUBERTY
We include growth parameters in this review as one aspect of pubertal development and not as a measure of fertility. Bone age, height, and weight have been studied in children with SCA, and multiple studies have concluded that all three parameters are decreased as compared to healthy controls. Because there is limited data on the height of adult men with SCA, those studies are considered in this section along with studies on growth in children with SCA.
Early studies have found that height is decreased in men with SCA at all ages. In a study done in 1974, Friedman et al. found that all eight men with SCD in their study were below average in height, ranging from 159 to 175 cm. one of the eight men was considered below normal in height, although the study did not specify what was considered 'normal. ' In 1975, Olambiwonnu et al. measured the height and weight of 40 children with SCA and compared it to the mean height of normal controls. They found that while six out of seven boys ages 5-11 were within one standard deviation of the normal mean for both height and weight, only three out of 13 boys ages 11-16 were within one standard deviation and the rest fell below one standard deviation. This data suggests growth failure or delay in boys with SCA.
The largest of all the growth studies to date was published in 1984 by Platt et al.- known as the Cooperative Study of Sickle Cell Disease (CSSCD)-and included 2115 patients with SCD from 2 to 25 years old. The researchers found that boys and young men with SCA were significantly shorter than their peers and weighed significantly less across all ages.
Several other studies published afterwards have attempted to further characterize patterns of puberty in SCA children in regards to specific growth patterns and hormonal changes. In a prospective study, Zemel et al. (2007) found that the average bone age of 106 children with SCA was significantly delayed, particularly in males (by a mean of À1.7 years). There was no significant correlation of bone age in these patients with disease severity, nutritional status, or maternal education.
The same study (Zemel et al., 2007) found in a sample of 148 children (60 boys, 78 girls) with SCA that that 38% were below the 5th percentile for weight, height, or body mass index at some point over the 4 years of the study. Other studies have reported similar findings, including a 1994 survey by Henderson et al. of 63 children with SCA in Baltimore that found 25% were below the 5th percentile for weight, height, or BMI. Another longitudinal study from 2009 by Rhodes et al. found that the rate of height growth in 19 boys with SCA was lower than controls one and two years after the beginning of the study when measured in percentage change. After one year, height change from baseline for subjects was 3.20 vs. 4.04% in controls (not significantly different). After two years, values were 6.46 vs. 8.86% (p < 0.05). Weight increased at a similar rate in both groups, although fat free mass was calculated to increase at a significantly lower rate in boys with SCA (20.3 vs. 30 .5% at 2 years, p < 0.05).
A review by Al-Saqladi et al. (2008) covers many of the studies performed on growth in children with SCA, which goes into more detail about height, weight, growth velocity, bone age, body measurements, and nutritional status than the information described above.
Effect of treatment on growth
In a prospective study, Wang et al. (2005) compared the height, weight, and BMI of 53 children with SCD receiving longterm transfusions vs. 41 receiving standard care. As expected, both groups were below average height, weight, and BMI as compared to normal children, and there was no significant difference between the two groups at the beginning of the study. Researchers found that after 2 years, those children receiving transfusions every 3-5 weeks approached normal average values in height and weight, whereas children who did not receive transfusions did not experience the same increase in growth velocity. Height growth velocity in children receiving transfusions was 0.56 cm/mo vs. 0.47 cm/mo in children receiving standard care (not significantly greater). Weight growth velocity was 0.41 kg/mo vs. 0.25 kg/mo (p < 0.05).
Another concern with frequent transfusions is organ damage caused by iron overload, which can lead to endocrinopathy among other problems. A study published in 2006 by Fung et al. looked at 142 with thalessemia vs. 199 subjects with SCD of various ages who were deemed to be iron-overloaded. One hundred nine non-iron-overloaded SCD subjects were used as controls. Iron-overloaded thalessemia subjects were more six times likely to have growth failure than iron-overloaded SCD subjects (p < 0.001), when growth failure was defined as requiring growth hormone therapy or a height of more than 2.5 standard deviations below the age and gender-specific median in the United States set by the Centers for Disease Control. There was no significant difference in growth failure between iron-overloaded and non-iron-overloaded SCD controls.
Wang et al. (same first author as 'Wang et al. (2005) ' with a different group of researchers) looked at the effect of hydroxyurea treatment on growth in children with SCA in another prospective study published in 2002, with the concern that hydroxyurea may be detrimental to growth because of its 680 Andrology, 2017, 5, 679-690 antimetabolite properties. Height and weight were similar between children who were on pre-treatment and treatment, and there was no significant difference in growth velocity between the two groups. The study was limited by a small sample size: 68 children were studied in total, including 40 boys (Table 1) .
PHYSICAL CHANGES DURING PUBERTY
Pubertal delay has been observed clinically in several studies as measured by body and facial hair growth and other aspects of Tanner staging. Delays in Tanner stage have been shown in both cross-sectional and prospective studies.
Early publications noted that patients with SCA had delayed puberty and less body and facial hair compared to cohorts with normal hemoglobin. Friedman et al. (1974) reported that all eight patients in their study had onset of puberty between 17 and 20 years of age. These patients also claimed that they shaved less and had less body hair than other members of their family. Abbasi et al. found delays in pubic hair growth according to the Tanner scale, and pubic hair remained underdeveloped even as adults. The average age of those at stage 4 was between 25-30 years, whereas controls had reached stage 5 by the average age of 16. In addition, 14 out of 32 patients (age 17-64) did not have any facial hair, none of the patients had acne, and two had mild gynecomastia.
The largest of these studies, the CSSCD (Platt et al., 1984) , found that children with SCD reached all Tanner stages (2-5) for pubic hair and genitalia development at an older age than expected. Zemel et al. also compared Tanner staging in children with SCA with published norms. The data from their study showed Tanner stage delays in boys, consistent with the CSSCD results.
There have been two longitudinal studies on physical changes of puberty in boys with SCA. Singhal et al. (1994) found that 44 boys with SCA reached Tanner stage 2 an average of 1.7 years later than peers with normal hemoglobin. In Rhodes et al. (2009) , the subjects and control group were matched at the beginning of the study for Tanner stage in addition to height and weight, and 90% of subjects were at Tanner stage 2. By the end of the study 2 years later, only 6% of 19 male subjects with SCA had progressed to stage 4, compared with 47% of male controls. The study did not specify which parameters were used for staging.
Another study from Brazil published in by Martins et al. (2015) described their findings of late puberty and overall underdevelopment in a sample of 15 adult male patients with SCD (median age: 27) as compared to two control groups: cohorts in the same socioeconomic status (healthy patients' relatives) and cohorts from a group of hospital workers and medical students. Tanner stages of most patients and all controls were stage 5 for genitalia and pubic hair development, although one patient was stage 3 for genitalia and pubic hair and two patients were stage 5 for genitalia and stage 4 for pubic hair. The age of puberty onset, hair development, voice change, and first ejaculation were all later in patients vs. control groups, with no significant differences noted between the two control groups.
Effect of treatment on pubertal physical changes
There have been few studies that have looked at whether blood transfusion has an effect on pubertal development. One patient from 'Friedman et al. (1974) ' reported developing pubic and axillary hair after he began receiving periodic transfusions at the age of 29, but no case studies have been published on such a case. Fung et al. (2006) found that iron-overloaded vs. non-ironoverloaded subjects with SCD had no significant difference in Tanner stage achievement or need for androgen-replacement therapy, and Zemel et al. (2007) found that blood transfusion status did not appear to have an effect on Tanner stage development.
Children with SCA who were treated with hydroxyurea appeared to attain Tanner stages at ages comparable to averages reported by the CSSCD (Wang et al., 2002) . Around 500 children have had HSCT with myeloablation with a 95% cure rate. Although HSCT has been shown to cause hypogonadism (this will be elaborated on in sections below), it does not appear to affect pubertal development. Lukusa et al. (2009) found that five male SCA patients who were prepubertal prior to transplant had all reached Tanner stage 5 by the time of the study, suggesting that children who receive HSCT can expect to go through puberty normally (Table 2) .
HORMONAL CHANGES DURING PUBERTY
Testosterone, luteinizing hormone, and follicle-stimulating hormone levels have been measured in boys and young men with SCA to determine whether the cause of pubertal delay is from testicular failure or pituitary/hypothalamic dysfunction. So far, the data have been inconclusive. This section explores the research on hormone levels in relation to puberty.
One of the first studies to measure LH and FSH levels in children with SCA was conducted by Olambiwonnu et al., 1975 . The data was divided by age group (5-10 vs. 11-16) and Tanner stage (1-2 vs. 3-4). In boys with SCA in the age 5-10 and Tanner stage 1-2 groups, they found significantly higher LH and mildly lower FSH (not significant) than the control group. Children 11-16 and Tanner 3-4 had no significant differences in LH and FSH as compared to controls. The increased LH suggests impaired testicular function, but since FSH was not elevated and hormones normalize later in puberty, the degree of testicular dysfunction is likely limited and transient.
Singhal et al. published a study in 1995 on 10 Jamaican boys with SCA who had shown no signs of puberty by age 16, attempting to uncover the cause of extreme growth delay seen in some boys with SCA. They hypothesized that the delay was as a result of either high resting energy expenditure or endocrine abnormalities. Resting metabolic rate in their sample was found to be similar to other boys with SCA who had gone through puberty normally. However, subjects were found to have high basal FSH levels (mean: 7.4 IU/L) compared to normal adults (1.2 IU/L) and growth-delayed boys with normal hemoglobin (1.5 IU/L), suggesting primary testicular failure. Five out of the 10 boys also had impaired or no response of testosterone levels to HCG stimulation. In addition, the researchers found that half the group also had impaired growth hormone secretion, and concluded that growth retardation may be the result of impaired testicular function and/or impaired growth hormone secretion. Rhodes et al. (2009) found no statistical difference in testosterone level between 19 boys with SCA vs. controls.
In 2013, Ozen et al. studied a group of 50 Turkish children with SCD between 4 and 18 years old. Of the 35 boys in the study, one had hypergonadotropic hypogonadism, with elevated basal LH and FSH and decreased testosterone levels as compared to normal values; three of the boys had small testes and decreased testosterone levels, but LH levels within normal limits. Martins et al. (2015) also studied testosterone levels in their sample. Mean basal testosterone levels were lower in patients, but the difference compared to control groups was not significant, in contrast to findings in earlier studies. Testosterone levels increased at a similar rate as controls after hCG stimulation, suggesting normal Leydig cell function. The group concluded that the clinical hypogonadism observed in male SCA patients was likely not the result of testicular dysfunction. Furthermore, response to hCG stimulation is those patients with low testosterone was normal, suggesting that pituitary or hypothalamic dysfunction may be responsible for pubertal delay.
Modebe & Ezeh (1995) hypothesized in their study that gonadal dysfunction measured in men with SCA could be a result of constitutional growth delay. They studied a group of 22 adult men with SCA to see if gonadal function would improve with increased age. Patients were divided into those younger and older than 25 years. Ten out of 22 patients had decreased testosterone levels; FSH, LH, and prolactin were within normal range for all patients and controls. There was no significant difference in hormone levels between patients younger and older than 25. However, the researchers found differences in genitalia development, semen analysis, and sexual performance between the age groups, which will be described in more detail in the 'Infertility' section below. Three of these studies also looked for other hormone abnormalities. Singhal et al. (1995) found cortisol secretion, free T4, T3, and TSH to be normal in all 10 boys with extreme growth retardation. Rhodes et al. (2009) found no statistical difference in thyroid hormone, growth hormone, leptin, or insulin levels between 33 children (19 male, 14 female) with SCA vs. controls. Ozen et al. (2013) found that 1 in 50 boys had central hypothyroidism, with normal growth and pubertal development, but low free T4 with normal TSH that did not respond sufficiently to TRH stimulation (Table 3) .
REPRODUCTIVE ORGANS IN ADULTS
Testicular length and volume have been shown to be significantly decreased in men with SCA as compared to normal controls in multiple studies.
In 'Friedman et al. (1974) ,' four out of eight patients with SCD had testicular size below normal as measured in centimeters and the other four patients were in the lower range of normal, although the definition of normal was not specified. Seven out of eight patients had low testicular volume using measurements from a Prader orchidometer. Abbasi et al. (1976) similarly found that the mean testicular length of 14 patients with SCA were significantly decreased compared to normal black men: patients had an average testicular length of 3.5 cm, vs. the normal value of 4.6 cm (p < 0.001), normal values were taken from an unrelated study from 1972). Testicular length of patients were also positively correlated with levels of androstenedione (p < 0.005), testosterone (p < 0.001), and dihydrotestosterone (p < 0.001). Modebe & Ezeh (1995) studied a sample size of 22 men with SCA and found that half the patients had a testicular volume less than two standard deviations below the mean of the control group (mean: 4.3 cm 3 vs. 7.8 cm 3 , p < 0.001). Patients under 25 years of age also had significantly less testicular volume than patients over 25 (mean: 3.7 cm 3 vs. 5.1 cm 3 , p < 0.02), which may suggested delayed development of the testes. Martins et al. (2015) found that testicular width (1.69 cm vs. 2.18 cm, p < 0.0001) and volume (17.93 cm 3 vs. 25.50 cm 3 , p < 0.0001) were significantly lower in patients with SCA compared to healthy relatives of the patients. Martins et al. (2015) also found that penis length was also shorter in men with SCA (9.9 cm vs. 11.0 cm, p-value not provided) (Table 4) .
HORMONE LEVELS IN ADULTS
Five out of seven studies that will be mentioned in this section found men with SCA have low testosterone levels. Although there have been no conclusive results on how LH and FSH levels of men with SCA differ from normal controls, most existing studies found evidence of abnormal levels in their sample groups. Prolactin levels found to be elevated in one study and normal in another.
Several studies on the hormone levels of SCA patients were performed before the 1980s, but they were limited by small sample sizes and had conflicting results. In 1974, Friedman et al. measured LH, FSH, and testosterone in eight adult patients with SCD and found that all patients had FSH and testosterone in the normal range, but two patients had elevated LH levels. In 1976, Abbasi et al. also measured the same hormones in 14 patients and found elevated LH and FSH, in addition to low male hormones, and suggested that male SCA patients had primary hypogonadism. In 1980, Dada & Nduka found decreased LH, FSH, and testosterone in 19 men with SCD, suggesting pituitary failure rather than testicular failure.
In 1987, Osegbe and Akinyanju also measured LH, FSH, and testosterone in the serum of men with SCD. In a sample size of 33 adult male subjects, there was no significant difference in FSH and LH levels as compared to the control group, although eight of the subjects had elevated FSH vs. none of the control group. Of those with elevated FSH, four subjects had significantly elevated LH. None of the subjects had low gonadotropin levels. Elevated FSH in subjects suggest that they had primary testicular failure, while their pituitary function remained intact. The study also pointed out that half of the men with elevated FSH had normal LH, and proposed that that the seminiferous tubules are more susceptible to damage from the disease than Leydig cells. Mean testosterone, similar to results from earlier studies, was significantly lower than the control group. Conversely, in a study published in 2012, Taddesse et al. found that eight out of 24 men with SCD had below normal testosterone levels, and of those eight men, either FSH or LH were low or inappropriately normal, suggesting pituitary failure.
As mentioned previously in the 'Puberty' section, Martins et al. (2015) found that testosterone was not significantly decreased in male patients with SCA, in contrast to other studies. The patients they studied also had an adequate increase in testosterone in response to hCG stimulation, suggesting that testicular function was intact. Osegbe & Akinyanju (1987) also found that their sample group had significantly elevated prolactin. Hyperprolactinemia in men has been linked to decreased testosterone as a result of gonadotropin suppression, oligospermia, impotence, and infertility (Melmed & Jameson, 2012) .
Effect of treatment on hormone levels
A few studies have looked at how SCA treatments can affect hormone levels. Soliman et al. (2013) measured testosterone, LH, and FSH levels in male SCD patients before and 7 days after packed red cell transfusion. All of the patients had been receiving transfusions from childhood and were on regular chelation therapy. After transfusion, there was a significant increase in all three hormones (p < 0.05). The same study also performed semen analysis on the patients, and the results are described in the next section. Although there is some evidence of increased iron deposition in the anterior pituitary gland in chronically transfused thalessemia patients associated with hypogonadism (Noetzli et al., 2012) , we were unable to find any similar studies on patients with SCA.
As previously mentioned, HSCT has been shown to be an effective cure for SCA in children, and treated children can be expected to progress through Tanner stages normally. Between 2004 and 2013, 30 adult patients enrolled in the NIH clinical trial, and 26 of those patients had complete reversal of the disease with few complications (Hsieh et al., 2014) . Myeloablative conditioning for stem cell transplant has been shown to decrease fertility but few studies have followed such effects on SCA patients who have received HSCT (Tichelli & Rovo, 2013) . One of these studies, 'Walters et al. (2010) ,' found below normal testosterone levels in 10 of 13 male patients who had undergone HSCT for SCD. Four of the 13 patients had low LH and FSH, and the other nine patients had values within the normal range. All 13 patients were over the age of 14, with a median age of 21.6. This data suggests that most of these patients had hypogonadotropic hypogonadism.
Although existing research suggests that chronic opioid therapy can cause clinically significant hypogonadotropic hypogonadism (Elliot et al., 2011)-we were unable to find any studies on the effect of opioid use on the reproductive system specifically in patients with SCA. Opioids remain one of the most commonly used treatments for pain in SCD. Han et al. (2016) found that 75% of 203 patients with SCD required some kind of opioid in a period of 12 months. Smith et al. (2015) found that 219 of 232 subjects with SCD reported at least one day of pain at home in a period of up to 6 months. 85.8% of those 219 patients used opioids during the study. Furthermore, it is estimated that hypogonadal effects can be expected with opioid doses exceeding 100-200 mg oral morphine equivalents (OME) daily (Elliot et al., 2011) , while Han et al. (2016) found that the median daily opioid dose of the patients studied was 6.1 mg OME and only 13% of patients used more than 50 mg OME daily. More research is needed on this area (Table 5) .
SEMEN ANALYSIS
Studies before 1990 using semen analysis of men with SCA have found that sperm density, motility, and morphology were reduced in these patients. In their paper from 1974, Friedman et al. also described their findings on semen analysis of four patients: Three of the patients had oligospermia. Another study from 1981 by Osegbe et al. on a sample of 23 Nigerian men with SCD showed significant reduction of sperm density, motility, and morphology as compared to a fertile control group from the same community (p < 0.001). There was no difference in semen volume between the two groups.
A similar study published in 1988 by Agbaraji et al. on patients from the sickle cell clinic at Howard University Center found that a random sample of 25 men from the clinic have significant reductions in sperm density (p < 0.03), motility (p < 0.0002), and normal morphology (p < 0.0001), consistent with the findings of 'Osegbe et al. (1981) .' Normal morphology was defined as having 60% or more oval-headed spermatozoa. In contrast to 'Osegbe et al. (1981) ,' however, this study also found a significant decrease in semen volume as compared to the control group (p < 0.02).
Modebe & Ezeh (1995) looked at the same sperm parameters as the two studies previously mentioned. Six out of 22 patients were unable to produce a sperm sample for study, two patients refused to produce a sample. The mean density, motility, and morphology of the remaining 14 patients were reduced compared to normal controls (p < 0.001). Semen volume was reduced, but not significantly, similar to what Osegbe et al. (1981) found in their study. 57% of patients had inadequate sperm density (with 'adequate' defined as density >20 9 10 6 spermatozoa/mL), whereas all controls had adequate density. The same study also found reduced sperm count in patients under 25 years of age, although not statistically significant, although it is of note that the eight patients who were unable or refused to produce a sperm sample were all under 25. Two papers on the effect on HU therapy on fertility tested the semen samples of men before initiation of therapy. Berthaut et al. (2008) found that of 76 samples from 34 male patients who had never received treatment with HU, 40.3% had decreased sperm count and 25.7% had abnormal semen volume, 9% of the samples had semen with all normal parameters. Voskaridou et al. (2010) found nine out of 15 SCD patients were oligospermic and two out of 15 azoospermic prior to HU therapy.
Effect of treatment on semen analysis
Blood transfusion has been shown to be beneficial, at least in the short term, for semen quality. Seven days after packed red cell transfusion, the patients from 'Soliman et al. (2013) ' had significantly increased sperm count and motility (p < 0.05), which was correlated with the increased in testosterone (p = 0.01). It is interesting to note that in 'Friedman et al. (1974) ,' the one man who had a normal semen analysis (in addition to normal LH and testosterone) had been receiving chronic blood transfusions for relief from painful sickling episodes. He was the same man mentioned previously (in the 'Puberty: Physical Changes' section) who developed axillary and pubic hair after starting transfusions at the age of 29.
There had been several studies showing sperm abnormalities in murines after treatment with hydroxyurea, but little data for humans prior to 1998 (Jones et al., 2009) . In 2000, the first and only case study on a patient who developed reversible azoospermia after starting hydroxyurea treatment was published (Garozzo et al., 2000) . From then, several papers have been done on the effect of hydroxyurea on fertility in sickle cell patients, which have demonstrated that hydroxyurea is linked to oligospermia and other sperm abnormalities. Some of these studies have also noted that fertility appeared to be preserved in these patients, as a few of them have fathered healthy children while on treatment.
Grigg (2007) looked retrospectively at four adult men (three had SCD, one had polycythemia vera) who were treated with doses of hydroxyurea ranging from 1000-1500 mg/day over varying durations. One of these patients (polycythemia vera) had azoospermia after ten years of therapy, but recovered sperm count 3 months after stopping therapy (although with abnormal morphology and impaired motility) and became azoospermic again 6 months after restarting therapy. The second patient (SCD) was tested after 17 months of therapy and had reduced sperm motility, which did not improve 32 months after stopping therapy. The third patient (SCD) had low sperm count but normal morphology and motility after stopping HU therapy (on for 4 years) for one year. The fourth patient (SCD) had low sperm count, normal motility, and abnormal morphology at 8 months, 2 years, and 4 years after starting HU therapy. From this data, the researchers concluded that HU therapy made lead to decreased sperm production and/or altered sperm morphology both during and after therapy, and these effects are at least partially reversible with the cessation of therapy.
In another retrospective study by Berthaut et al., 2008 , six samples collected from five patients who were on treatment all had abnormal spermatozoa, mainly reduced sperm count and motility. Twenty-six samples collected from eight patients who had interrupted treatment interrupted all had abnormal semen analysis in all parameters except volume, and one patient was azoospermic. In four patients, there was data on sperm samples before and after treatment: three of them had alteration in sperm production (volume, concentration, motility, and/or morphology) after treatment (including one who became azoospermic), one patient's sperm parameters remained unchanged. Comparison of sperm parameters of samples collected from 30 patients before treatment and four different patients after treatment did not show any statistical difference between the two groups. It appears that fertility can be preserved in patients receiving HU therapy: pregnancies by two men receiving HU therapy resulted in normal birth, and partners of three men who had been receiving HU therapy conceived within 2 years. In 2009, Lukusa et al. published a study on semen samples of patients who were either receiving HU or had been treated with HSCT. The researchers found that two of four of SCA patients on HU therapy were azoospermic and the other two were oligospermic. Azoospermic patients had been on HU therapy for 12 and 15 years, oligospermic patients had been on HU therapy for 8 and 9 years.
HSCT has also been shown to affect semen quality. In 'Lukusa et al. (2009) ,' six patients who received HSCT were tested on various fertility measures. One of the patients was an adult at the time of transplant and was found to have mild oligozoospermia. Three of the children who had received total lymphoid irradiation had been azoospermic at the time of transplant, and remained azoospermic at the time of the study at 15, 16, and 19 years of age. Two of the children were under the age of five at the time of transplant and received only chemotherapy: one had a normal sperm count, while the other had oligozoospermia. Because these patients have been cured, we can assume any reduction in fertility is the result of treatment or damage from disease that occurred early in life. The study speculates that receiving HSCT at a younger age may have preserved spermatogenesis either because germ cells are more resistant to chemotherapy in infants or not enough damage secondary to testicular infarction had occurred. The same study also looked at LH, FSH, and testosterone levels and did not find any particular trend, although four out of the six patients had below normal testosterone. Another four patients had elevated FSH, although there did not appear to be an association with testosterone levels. The researchers did not address the fact that the younger patients did not receive radiation therapy (Table 6 ).
PROPOSED MECHANISMS OF HYPOGONADISM
Studies have consistently shown hypogonadism-including both hormonal and semen abnormalities-in male patients with SCA. So far, besides the side effects of HU therapy and HSCT mentioned in the sections above, explanations for what causes hypogonadism in these patients are still speculation, but most of these studies attribute the reason to repeated vaso-occlusion of the hypothalamic-pituitary or testicular vessels secondary to sickling. At least five cases of testicular infarction in sickle cell patients have been reported. One case study was published in 2003 by Li et al. on a 37-year-old African American man with SCD who presented with right testicular pain and two lesions in the right testis. Histologic exam showed necrotic seminiferous tubules filled with debris and inflammatory infiltrate in one lesion, while the other lesion showed necrotic tubules but no debris or infiltrate. Fibrotic scarring and hemosiderin deposition were found in other areas of the testis. The doctors proposed that these findings are the result of repeated testicular infarctions, which could be a mechanism of testicular failure and impaired fertility in male SCA patients.
Although pituitary infarctions as a result of sickling red blood cells has been reported, there has been no recent evidence that it is a cause of hypopituitarism. (Dada & Nduka, 1976; Athanasou et al., 1985) .
There has been some evidence that growth retardation and hypogonadism is linked to zinc deficiency in patients with SCA. Abbasi et al. (1976) found decreased zinc concentration in the hairs and erythrocytes of 29 patients with SCA compared to normal controls. Those with low testosterone levels had the lowest levels of zinc in their erythrocytes. Patients with the most pubic hair had the highest levels of erythrocyte zinc. There have also been studies that show zinc supplementation increased growth rates in children with SCD in height and arm circumference. Those children with SCD receiving zinc supplementation also had closer to normal values of height-for-age and weightfor-age. (Prasad, 2002; Zemel et al., 2007) .
PRIAPISM
Priapism-particularly the type that is a result of decreased venous outflow, as seen in SCA-can lead to erectile dysfunction by causing corporal edema, necrosis, and fibrosis if left untreated. Although the exact mechanism is unclear, it is thought that sickling of red blood cells in the corpora cavernosa leads to venous stasis, thereby decreasing local oxygen and pH, which leads to further sickling of cells and and stasis. Stuttering priapism describes a recurring pattern of ischemic priapism. (Spycher & Hauri, 1986; Bruno et al., 2001; Broderick, 2012) .
A significant proportion of SCD patients reports a history of priapism, with most studies citing from 35 to 42% of patients (Emond et al., 1980; Fowler et al., 1991; Burnett et al., 1995; Adeyoju et al., 2002) . One relatively large study of 130 patients with SCD using a questionnaire found 29% of patients with a history of priapism had erectile dysfunction and 24% of patients with a history of priapism reported sexual dissatisfaction-one reason being the fear of priapism (Adeyoju et al., 2002) .
The standard treatment for an acute episode of ischemic priapism is aspiration of blood from the corpora cavernosa (in order to decompress the penis) and administration of a sympathomimetic drug. The drug of choice is phenylephrine because of its selective alpha-1 adrenergic agonistic effects, which works by causing the smooth muscle of the penis to contract (Broderick, 2012 ). Several studies have tested the effectiveness of alpha agonists as prophylaxis for stuttering priapism in SCD with mixed results. One international study-the largest of these studies-tested the effectiveness of etilefrine and ephedrine as prophylaxis against a placebo. Patients were divided into four groups: 15 mg ephedrine daily, 30 mg ephedrine daily, 50 mg etilefrine daily, and placebo. After 6 months, there was no significant difference in the number of weekly episodes of priapism between the four groups (after adjusting for the baseline number of attacks). There was also no difference in the average pain score during attacks. The researchers did notice a reduction in the number of priapism episodes lasting longer than 4 hours, but this reduction was not significant (Olujohungbe et al., 2011) .
It is unclear if sex hormones levels-particularly testosterone -has an effect on the incidence of priapism in SCA, and if so, whether testosterone exacerbates or decreases the incidence of priapism. Most studies on this topic have been aimed at determining whether drugs that decrease testosterone levels or lessen the effects of testosterone-such as GnRH analogs, 5-alphareductase inhibitors, androgen receptor antagonists, estrogens, and ketoconazole-can be used as prophylaxis for priapism. The studies that report effectiveness of these drugs either have very small sample sizes or are case studies, and there is currently a lack of controlled trials. A list of references and a more detailed summary of these studies can be found in the review Priapism and Sickle-Cell Anemia: Diagnosis and Nonsurgical Therapy by Broderick (2012) .
If antiandrogens decrease the frequency of priapism episodes, then the question arises of whether testosterone replacement therapy for hypogonadism could trigger or worsen priapism. In 2013, Morrison et al. published a prospective study on seven men with SCA who were given testosterone replacement therapy for hypogonadism. Therapy consisted of 1 g of testosterone undecanoate intramuscularly at 0 weeks, 6 weeks, then every 3 months for 12 months. Subjects completed questionnaires prior to treatment, 6 months into treatment, and 12 months into treatment. Two validated instruments and one screening tool was used to determine any benefits of the therapy, and a nonvalidated questionnaire was used to assess the history and frequency of priapism. Therapy resulted in significantly improved sexual desire, intercourse satisfaction, and overall satisfaction, as well as significantly less reduced libido and erections. Of the four out of seven men who reported a history of priapism, there was no increase in the frequency of episodes. One of the men who gave no history of priapism had an episode of priapism that awoke him at night and lasted 30 min before resolving spontaneously. The researchers concluded that testosterone replacement is safe and has therapeutic benefit for men with SCA with hypogonadism.
The same group performed another study published in 2015 on whether testosterone deficiency is related to priaprism in SCA. Of a group of 50 men with SCA, 48% had a history of priapism. There was no significant difference in the mean total testosterone level or percentage who have testosterone deficiency (defined as serum total testosterone <12 nmol/L) between those with and without a history of priapism. (Morrison et al., 2015) .
PREGNANCY RATES
There are no good data on the rates and outcomes of pregnancy in partners of men with SCA, but we know that both men and women with SCA have been able to conceive healthy children. Modebe & Ezeh (1995) found that nine out of 11 married men from their control group had children, whereas only one out of three married men with SCA had fathered a child. These claims were not verified and no conclusions were drawn. A study on the effect of hydroxyurea on sperm parameters by Berthaut et al. (2008) also surveyed the control and sample groups for pregnancy rates as a measure of fertility, and they found that 17 of 42 men with SCD living with a partner had caused 36 pregnancies (one with in vitro fertilization with sperm cryopreserved prior to HU therapy). Of the 36 pregnancies, there were 29 normal births, three spontaneous miscarriages (all for the same patient), and four abortions. There were two pregnancies in partners of two patients who had been on HU treatment which resulted in normal births. The partners of three other patients on HU were able to conceive within 2 years-birth outcomes were unknown at the time of the study.
It appears treatment with HU does not cause infertility, at least in some patients. In a prospective study by Voskaridou et al. (2010) on 131 men with SCD receiving HU therapy, six male patients caused pregnancy in a partner that resulted in normal delivery after discontinuing therapy for 4 months and two of the men's partners conceived and had normal deliveries while the men were on therapy. One of these men fathered two healthy children on therapy. No birth defects were noted in children of men who were on HU therapy.
CONCLUSION
We can draw only limited conclusions from the current research on the reproductive issues in male patients with SCA. So far, we know that boys with SCA display later onset of puberty than normal. There are also measurable differences in genitalia and secondary sexual characteristics in male patients with SCA, including less facial and body hair, delayed attainment of Tanner stages for pubic hair and genitalia development, and smaller testicular size and shorter penis length in adult men. Both children and adults with SCA exhibit hormonal abnormalities, particularly low levels of testosterone in pubescent boys and adult men. LH and FSH values may also be deranged in these patients, although inconsistently: studies included in this review found both elevated, normal, or decreased levels of both hormones. Semen abnormalities include reduced sperm density and motility, reduced number of spermatozoa with normal morphology, and reduced semen volume. There is currently a lack of studies on whether the signs of hypogonadism and hormone and semen abnormalities are correlated with decreased libido and erectile dysfunction in men with SCA.
While the SCA disease process itself appears to play a role the reproductive issues described above, treatment of SCA has also been shown to affect fertility in patients. Transfusion may not affect growth and puberty in patients with SCD, but appears to have a positive effect on levels of testosterone, LH, and FSH. In addition, iron overload does not seem to cause endocrine organ damage in patients with SCA as it does in patients with thalessemia, suggesting that the disease process may somehow be protective. Hydroxyurea treatment does not stunt growth or puberty, but has negative effects on semen quality. Although HSCT did not prevent normal pubertal development in several male subjects, it may cause lower than normal levels of testosterone, LH, and FSH. Meanwhile, the effect of chronic opioid therapy on the reproductive system in SCA has not yet been studied. More studies are needed to clarify and quantify the extent of treatment effect on sex organs, hormone production, and semen quality. It is also important be able to distinguish between abnormalities caused by treatment vs. the disease process.
Because present treatment options are focused on preventing and treating pain crises related to sickling episodes, detrimental effects on reproductive organs by the disease and its treatment may have been overlooked. Clinicians should pay attention to signs of hypogonadism and inquire about potential symptoms. Benefits and risks of treatment pertaining to the reproductive system should be discussed. Appropriate testing should be carried out to assess for hypogonadism if suspected, and in select patients, testosterone replacement therapy may be considered.
Several other questions arise from our conclusions in this review. When it comes to measures of fertility, such as testosterone levels and semen quality, it is apparent that some men with SCA are more negatively affected than others, although it is unclear why. More research is needed on whether disease severity plays a role. We also do not know how much of reproductive issues in patients with SCA is related to the disease process and how much is simply a result of having a chronic disease. If chronic disease really does cause growth and puberty delay, hypogonadism, and reduced spermatozoa quality, would aggressive treatment with transfusions and hydroxyurea at an early age improve these parameters? Furthermore, should these patients receive hormonal therapy at an early age?
Lastly, it would be interesting to consider the reproductive decisions of people with SCA, either through surveys or interviews. As mentioned earlier, some of these men have fathered healthy children, and one study has shown that both men and women with SCA are concerned about their children having to suffer the same disease. (Gallo et al., 2010) Gaining a better understanding of the reproductive concerns in patients with SCA will allow us to tailor our research to what is relevant.
